Theratechnologies Inc.
The biopharmaceutical company has developed and commercialized EGRIFTA SV (tesamorelin for injection), an injection for the reduction of excess abdominal fat in HIV-infected patients with lipodystrophy, and Trogarzo (ibalizumab-uiyk), an injection for the treatment of HIV with a new mechanism of action. The company is also developing tesamorelin for the treatment of non-alcoholic steatohepatitis (NASH).
Overview
Overview | |
|---|---|
Country | Canada |
State | |
Employees | 103 |
Founded | 1993 |
Financials | |
|---|---|
Market Capitalization | 65.98M |
Revenue | 60.71M |
Operating Income | 2.76M |
Operating Margin | 4.55% |
Net Income | -5.14M |
Ranking
Operating Income
Operating Income Ranking | |
|---|---|
All | 2822 / 5373 |
Sector : Healthcare | 206 / 1144 |
Industry : Biotechnology | 33 / 645 |
Market Capitalization
Market Capitalization Ranking | |
|---|---|
All | 4368 / 5565 |
Sector : Healthcare | 775 / 1182 |
Industry : Biotechnology | 426 / 670 |
Net Income
Net Income Ranking | |
|---|---|
All | 3211 / 5436 |
Sector : Healthcare | 255 / 1164 |
Industry : Biotechnology | 68 / 659 |
Employees
Employees Ranking | |
|---|---|
All | 4001 / 5330 |
Sector : Healthcare | 628 / 1174 |
Industry : Biotechnology | 248 / 667 |